Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 3No longer available 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Glioma 2Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

TIC10 compound 3trastuzumab deruxtecan 2umbralisib 1ublituximab 1pembrolizumab 1infigratinib 1enfortumab vedotin 1duvelisib 1blinatumomab 1belumosudil 1Rituximab 1KD025 1Gemcitabine 1Crizotinib 1Cisplatin 1Carboplatin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Has announcements × TIC10 compound × Clear all
NCT03295396 2025-07-28

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Jazz Pharmaceuticals

Phase 2 Terminated
73 enrolled 13 charts 1 FDA
CNS

Glioma

NCT03416530 2025-02-14

ONC201 in Pediatric H3 K27M Gliomas

Jazz Pharmaceuticals

Phase 1 Terminated
134 enrolled 1 FDA
CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT02525692 2024-12-24

Oral ONC201 in Adult Recurrent Glioblastoma

Jazz Pharmaceuticals

Phase 2 Terminated
84 enrolled 14 charts 1 FDA
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡